CYP2D6-genotyping in the assessment of the effectiveness of therapy with tamoxifen in patients with advanced hormone receptor-positive breast cancer
Автор: Liudmila N. lyubchenko, Margarita G. filippova, Nigyar I. mekhtieva, Tatyana A. shendrikova, Alexandra V. semyanikhina, Anton V. snegovoy
Журнал: Сибирский онкологический журнал @siboncoj
Рубрика: Обзоры
Статья в выпуске: 6 т.16, 2017 года.
Бесплатный доступ
Tamoxifen is a drug of choice for endocrine therapy of hormone receptor- positive breast cancer in women of reproductive age. The metabolic activity of tamoxifen is determined by the activity of the CYP2D6 enzyme encoded by the CYP2D6 gene: under the action of the enzyme, tamoxifen converts into the metabolically active form called endoxifen. Pharmacogenetic testing of the CYP2D6 gene in patients with hormone-positive breast cancer can help to predict response to therapy and assess the risk of side effects with the aim of improving long-term treatment outcomes.
Tamoxifen, pharmacogenetics testing, CYP2D6 gene, hormonotherapy, breast cancer
Короткий адрес: https://sciup.org/140254154
IDR: 140254154 | DOI: 10.21294/1814-4861-2017-16-6-73-85